Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
About this item
Full title
Author / Creator
Martínez-Sáez, Olga , Chic, Nuria , Pascual, Tomás , Adamo, Barbara , Vidal, Maria , González-Farré, Blanca , Sanfeliu, Esther , Schettini, Francesco , Conte, Benedetta , Brasó-Maristany, Fara , Rodríguez, Adela , Martínez, Débora , Galván, Patricia , Rodríguez, Ana Belén , Martinez, Antonio , Muñoz, Montserrat and Prat, Aleix
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinici...
Alternative Titles
Full title
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_82966bc1ef824877920c73977a48ab41
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_82966bc1ef824877920c73977a48ab41
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-020-01284-9
